Kwality Pharmaceuticals has received product registration for Bleomycin 15 IU in Mexico for sale and distribution, expanding its oncology portfolio in regulated markets.

Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas.

"This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally,” the company said.

The company expects to generate approximately 1 million USD in the first year of sales, with supplies commencing before the end of Q2FY26.

Headquartered in Amritsar, India, Kwality Pharmaceuticals is among the fastest pharmaceutical manufacturing companies for complex molecules in India.

It has a growing international footprint, supplying high-quality finished formulations to various countries across Europe, Latin America, Africa, Mena, GCC, Russia, Asia, and the CIS region.

The company reaffirmed its commitment to expanding access to high-quality medicines across global markets.